Hypertension Diagnostics, Inc. Newsroom


	Hypertension Diagnostics raises $2 million from private placement ST. PAUL, MN – March 27, 2002 – Hypertension Diagnostics, Inc. (NASDAQ SmallCap: HDII), announced today that it had raised $2,000,000 through a private placement of 8% Convertible Notes in the principal amount of $2,000,000 and warrants to purchase 250,000 shares of Common Stock of the Company. The Company intends to use the proceeds from the private placement as working capital.
	Greg H. Guettler, President of Hypertension Diagnostics, said, “The $2 million in additional funds will aid us in our continuing efforts to bring our CVProfilor® DO-2020 technology to physicians in key U.S. markets.” Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB, under the caption “Risk Factors,” as well as others not now anticipated. CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved. Investor Relations: Jens Dalsgaard and Tony Altavilla, Managing Directors Redwood Consultants, LLC Mill Valley, CA 94941 415-380-0500 Contact: Greg H. Guettler, President Return to the Main HDI Newsroom Back to Top

Copyright © 2009 Hypertension Diagnostics, Inc Last revised Wednesday February 11, 2009 HDI Legal Information